Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;5(9):1616-1621.
doi: 10.1002/hep4.1747. Epub 2021 Jun 5.

Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing Investigation

Affiliations

Alcohol-Associated Liver Disease Before and After COVID-19-An Overview and Call for Ongoing Investigation

Andrew M Moon et al. Hepatol Commun. 2021 Sep.

Abstract

The Coronavirus Disease 2019 (COVID-19) pandemic has exacted a heavy toll on patients with alcohol-associated liver disease (ALD) and alcohol use disorder (AUD). The collective burden of ALD and AUD was large and growing, even before the COVID-19 pandemic. There is accumulating evidence that this pandemic has had a large direct effect on these patients and is likely to produce indirect effects through delays in care, psychological strain, and increased alcohol use. Now a year into the pandemic, it is important that clinicians fully understand the effects of the COVID-19 pandemic on patients with ALD and AUD. To fill existing gaps in knowledge, the scientific community must set research priorities for patients with ALD regarding their risk of COVID-19, prevention/treatment of COVID-19, changes in alcohol use during the pandemic, best use of AUD treatments in the COVID-19 era, and downstream effects of this pandemic on ALD. Conclusion: The COVID-19 pandemic has already inflicted disproportionate harms on patients with ALD, and ongoing, focused research efforts will be critical to better understand the direct and collateral effects of this pandemic on ALD.

PubMed Disclaimer

References

    1. Marjot T, Moon AM, Cook JA, Abd‐Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS‐CoV‐2 infection in patients with chronic liver disease: an international registry study. J Hepatol 2021;74:567‐577. - PMC - PubMed
    1. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, et al. Predictors of outcomes of COVID‐19 in Patients with chronic liver disease: US multi‐center study. Clin Gastroenterol Hepatol 2020. Sep 17. 10.1016/j.cgh.2020.09.027. [Epub ahead of print] - DOI - PMC - PubMed
    1. Marjot T, Webb GJ, Barritt AS, Moon AM, Stamataki Z, Wong VW, et al. COVID‐19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021;18:348‐364. - PMC - PubMed
    1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA 2020;323:1061‐1069. - PMC - PubMed
    1. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12‐month alcohol use, high‐risk drinking, and DSM‐IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry 2017;74:911‐923. - PMC - PubMed